Citations

Clear

1446 citation(s) found for "Howard, F".

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort
Yanagihara, Ted K. , Dawson, Laura A., Yu, Jeong Il, Lawrence, Theodore S. , Kim, T S, Yan, Michael, Iwata, Hiromitsu , Nabavizadeh, Nima , Apisarnthanarax, Smith , Dunne, Emma M., Lock, Michael , Chuong, Michael D., Chiang, Chi Leung, Katoh, Norio , Sioshansi, Shirin, Numata, Kazushi, Liu, Howard , Wakatsuki, Masaru , Chen, YiXing, Pollom, Erqi L., Gkika, Eleni , Dutta, Debnarayan , Hajj, Carla , Hallemeier, Christopher L. , Feldman, Aharon, Romero, Alejandra Méndèz , Tan, Xianming , Tepper, Joel E. , Torres, Ferràn , Bergman, Alanah M., Crane, Christopher, Cuneo, Kyle C., Grindrod, Natalie, Grosu, Anca-Ligia, Far, R. El, Funaoka, Akihiro, Gilbert, Marissa, Itasaka, Satoshi , Lee, Sung Uk , Mases, Joel , Ogino, Hiroyuki , Qu, Vera , Park, Hee Chul, Rahmani, Ramtin, Shing, Lee Ann, Stanescu, Teodor, Thonglert, Kanokphorn , Toom, Wilhelm den , Uchinami, Yusuke , Zeng, Zhaochong, Moon, Andrew M , Yanagihara, Ted K , Lawrence, Theodore S , Kim, Tae Hyun , Iwata, Hiromitsu , Nabavizadeh, Nima , Apisarnthanarax, Smith , Lock, Michael I , Chuong, Michael , Chiang, Chi Leung , Scorsetti, Marta , Katoh, Norio , Liu, Howard Yu-Hao , Iwamoto, Hideki , Pollom, Erqi Liu , Gkika, Eleni , Jabbour, Salma K , Munoz-Schuffenegger, Pablo , Dutta, Debnarayan , Hajj, Carla , Ueno, Masayuki , Hallemeier, Christopher Leigh , Feldman, Aharon M , Méndèz Romero, Alejandra , Tan, Xianming , Tepper, Joel E , Torres, Ferran , Reig, Maria , Dawson, Laura A. , Yu, Jeong Il , Dunne, Emma Maria , Chuong, Michael D. , Numata, Kazushi , Mollà, Meritxell , Crane, Christopher H. , Cuneo, Kyle Clifford , Grindrod, Natalie , Franzese, Ciro , Gilbert, Marissa, Lee, Yoo Young , Lee, Ann‐Shing, Shirono, Tomotake , Stanescu, Teo

Mayo Clinic

Journal of Clinical Oncology | May 15, 2026 | Volume: 44 | Issue: 19 | Pages: 1784-1797

10.1200/jco-25-02399 | PMID 42139645 Get It

PURPOSE External beam radiation therapy (EBRT) has gained delayed acceptance as a recommended first-line treatment modality for patients with hepatocellular carcinoma (HCC), given limited evidence that it improves overall survival (OS). We analyzed individual patient data (IPD) from an international cohort to assess OS among patients with HCC treated with EBRT. METHODS We performed a systematic review of publications that assessed EBRT, met prespecified technical standards for HCC, and reported OS (search date December 15, 2022). Corresponding authors were invited to submit IPD for the study. We performed Kaplan-Meier survival analyses to determine OS and restricted mean survival time (RMST) stratified by Barcelona Clinic Liver Cancer (BCLC) stage and treatment status (ie, treatment-naïve and experienced). We performed random effects Cox proportional hazards modeling to assess clinical characteristics associated with OS. RESULTS Data were provided on 4,913 patients treated with EBRT with a median follow-up time of 5.0 years. The median OS was 6.8 years (95% CI, 5.7 to 8.7) for BCLC-0 and 4.6 years (95% CI, 4.1 to 5.1) for BCLC-A. Among treatment-naïve patients, the median OS was not reached (95% CI, 8.6 to not reached) for BCLC-0 and was 5.4 years (95% CI, 4.5 to 6.7) for BCLC-A. In multivariable models, more advanced BCLC stage, higher tumor burden, worse performance status, and Child-Pugh class B or C were associated with a higher risk of mortality. Ablative radiation dose and more recent year of treatment were associated with a reduced risk of death. CONCLUSION To our knowledge, this study represents the largest multinational cohort of patients with HCC treated with EBRT. OS outcomes with EBRT for very early- and early-stage HCC appear to be comparable with resection, thermal ablation, and other ablative locoregional therapies. These data support the inclusion of EBRT in the BCLC HCC clinical decision-making process.
Six-Month Outcomes in Children With COVID-19 or Multisystem Inflammatory Syndrome in Children
Howard, Leigh M. , Calvert, Alexis, Stopczynski, Tess , Klintworth, Steven R., Soslow, Jonathan H., Spieker, A, Hilmes, Melissa A. , Dalal, Aarti S., Ruth, Natasha, Mahle, William T. , Schneider, James, Michaels, Marian G., Acker, Karen P. , Danziger-Isakov, Lara, Gans, H, Orr, William B. , Choueiter, Nadine , Kantor, Paul F., Chandani, Harsha K., Chakraborty, Rana, Narula, Pramod, Rossano, Joseph, Singh, Rakesh K. , Trachtman, Rebecca, Pascual, Virginia , Martinez, Olivia M. , Diamond, Betty, Sanz, Ignacio, Boss, Jeremy M., Goldmuntz, E, Morrison, Yvonne, Welch, Beverly, Halasa, Natasha , Webber, Steven A. , Diamond, Betty , Dalal, Aarti , Wilkinson, James D. , Soslow, Jonathan H. , Spieker, Andrew J. , Moore, Paul E. , Ruth, Natasha M. , Michaels, Marian G , Danziger‐Isakov, Lara , Kelly, Matthew S. , Kantor, Paul Fraser , Chandnani, Harsha K., Chakraborty, Rana , Rossano, Joseph, Arditi, Moshe , Trachtman, Rebecca A. , Krams, Sheri M. , Sanz, Igñacio , Boss, Jeremy M. , Bridges, Nancy D. , Goldmuntz, Ellen

Mayo Clinic

Hospital Pediatrics | May 14, 2026 | Volume: 16 | Issue: 6 | Pages: 525-535

10.1542/hpeds.2025-008765 | PMID 42128419 Get It

OBJECTIVES We aimed to characterize the frequency of major complications of acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C) and adolescents present at 6 months after initial presentation. METHODS The Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM) study was a prospective cohort at 20 US pediatric academic medical centers. Individuals aged younger than 21 years meeting any of the following were enrolled: SARS-CoV-2 detection within 7 days, Centers for Disease Control and Prevention (CDC) MIS-C criteria, or CDC MIS-C criteria except having involvement of 1 organ system. The study was designed to assess the proportion of children with major complications (cardiovascular, pulmonary, gastrointestinal/hepatic, renal, and/or neurologic) 6 months after presentation. RESULTS Data were analyzed on 229 hospitalized participants: 59 with COVID-19 (mean age 10.4 years; SD, 5.5) and 170 with MIS-C (mean age 10.1 years; SD, 4.8). Overall, 42.8% were female, making up 55.9% and 38.2% of the COVID-19 and MIS-C groups, respectively. Overall, the frequencies of major complications at 6 months after initial presentation were: 16/195 (8.2%) cardiovascular, 11/154 (7.1%) pulmonary, 11/154 (7.1%) gastrointestinal/hepatic, 3/152 (2.0%) renal, and 3/189 (1.6%) neurologic. Organ system complications did not differ significantly between the COVID-19 and MIS-C groups. Six of 14 (42.9%) COVID-19 and 21/26 (80.7%) MIS-C participants with at least 1 six-month complication had no underlying medical condition that may have been associated with their complication(s). CONCLUSIONS Major complications were infrequent but observed in children without underlying medical conditions, underscoring the importance of prospective follow-up to optimize management and elucidate the complications associated with severe SARS-CoV-2 infection in children.
Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial
Vicini, Frank A. , Winter, Kathryn, Freedman, Gary M., Arthur, Douglas W., Rosenstein, Barry S. , Li, X. Allen , Halyard, Michele Y. , Woodward, Wendy A. , LYONS, JANICE, Tomberlin, Janice K., Seaward, Samantha A. , Cheston, Sally B. , Hoover, A. , Perera, Francisco E. , Poppe, Matthew M. , Petersen, Ivy A., Jhawar, S., Moughan, Jennifer, Movsas, B, White, Julia , Li, X. Allen , Woodward, Wendy A , Bleicher, Richard J , Taghian, Alphonse , Lyons, Janice , Seaward, Samantha A , Hoover, Andrew C , Anderson, Bethany M , Perera, Francisco E , Jhawar, Sachin R , Hijal, Tarek , Movsas, Benjamin , White, Julia R , Freedman, Gary M. , Bentzen, Søren M. , Anderson, Bethany M. , Perera, Francisco E, Petersen, Ivy A. , Jhawar, Sachin R. , Hijal, Tarek , Movsas, Benjamin

Mayo Clinic

Journal of Clinical Oncology | May 11, 2026 | Volume: 44 | Issue: 19 | Pages: 1798-1811

10.1200/jco-25-02465 | PMID 42114027 Get It

PURPOSE For patients with breast cancer undergoing breast conservation, escalating the dose (boost) of radiation to the lumpectomy cavity after whole-breast irradiation (WBI) reduces ipsilateral breast recurrence (IBR) but extends treatment duration. This phase III trial investigated whether boost delivery during WBI versus after WBI provides noninferior IBR and preserves cosmetic appearance. METHODS NRG/RTOG 1005 randomly assigned patients at higher risk for IBR after lumpectomy and axillary surgery to either a sequential boost of 12 Gy in six fractions(F) or 14 Gy in 7F after WBI of 50 Gy in 25F or 42.7 Gy in 16F (sequential arm) or a concurrent boost of 8 Gy in 15F of 0.53 Gy per day with WBI of 40 Gy in 15F (concurrent arm) using 3-dimensional conformal radiation therapy (RT) or intensity-modulated RT. Based on 1.59% 5-year IBR for the sequential arm, defining the noninferiority margin as a hazard ratio upper limit on the 90% CI of 2.12, 2,312 patients provide 80% power for noninferiority of IBR as first recurrence for the concurrent arm. Secondary end points included disease-free survival and overall survival, adverse events (AEs), and cosmetic outcomes. RESULTS Between May 24, 2011, and June 20, 2014, 2,354 patients were randomly assigned, with 2,255 eligible for analysis (sequential arm, n = 1,118; concurrent arm, n = 1,137). With median follow-up of 7.3 years, there were 56 IBR events; 5- and 7-year IBR were 2.1% and 2.2% on the sequential arm and 1.9% and 2.6% on the concurrent arm, respectively. The noninferiority criterion was met: HR (90% CI): 1.31 (0.84 to 2.04), P = .037. No differences were observed in AEs, cosmetic outcomes, or survival between arms. CONCLUSION Concurrent boost during WBI results in noninferior IBR compared with sequential boost without worsening toxicity or cosmetic outcomes and reduces overall treatment time.
The neurobiology of survivorship: Cognitive consequences of modern oncology
Mrugala, Maciej M, Monje, Michelle, Mrugala, Maciej , Monje, Michelle

Mayo Clinic

Neuro-Oncology Advances | May 6, 2026 | Volume: 8 | Issue: Supplement_5 | Pages: 1-2

10.1093/noajnl/vdag121 | PMID 42338465 Get It

MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma
Moassefi, Mana , Decker, Paul A. , Conte, Gian Marco , Kosel, Matthew L., Molinaro, Annette M. , Niederschweiberer, Moritz , Nikanpour, Yalda , Ruff, Michael W. , Burns, Terry C. , Farooq, Umar , Derdeyn, C, Jenkins, RB , Lachance, Daniel H , Eckel‐Passow, Jeanette E. , Kosel, Matthew , Niederschweiberer, Moritz A , Derdeyn, Colin P , Habermann, Thomas , Cerhan, James R , Greenlee, Jeremy D W , Howard, Matthew A , Slager, Susan L , Vaubel, Rachael A , Lachance, Daniel , Erickson, Bradley J , Tobin, W Oliver , Eckel-Passow, Jeanette E , Farooq, Umar , Conte, Gian Marco , Burns, Terry C , Moassefi, Mana , Decker, Paul A. , Kosel, Matthew , Molinaro, Annette M. , Derdeyn, Colin P. , Habermann, Thomas M. , Cerhan, James R. , Greenlee, Jeremy D.W. , Howard, Matthew A. , Slager, Susan L. , Vaubel, Rachael A. , Jenkins, Robert B. , Erickson, Bradley J.

Mayo Clinic

Cancer Research Communications | May 4, 2026 | Volume: 6 | Issue: 5 | Pages: 1168-1179

10.1158/2767-9764.crc-25-0710 | PMID 42081255 Get It

Abstract Glioblastoma (GBM), isocitrate dehydrogenase wild-type (IDHwt) and central nervous system diffuse large B-cell lymphoma (CNS-DLBCL) are aggressive brain tumors with overlapping MRI features, yet distinct treatment approaches. Noninvasive tools are needed to aid in differential diagnosis. Deep learning on T1 postcontrast and T2-weighted MRI sequences were used to differentiate GBM and CNS-DLBCL. A three-stage temporal study design was utilized. Model development was performed on 146 patients with CNS-DLBCL and 146 age-matched, sex-matched, and MRI year–matched patients with GBM diagnosed at Mayo Clinic between 1998 and 2019. Models were tested on independent temporal test cohorts. Initial testing included 240 independent GBM diagnosed at Mayo Clinic between 1998 and 2019. The prospective test cohort included 37 patients with CNS-DLBCL and 256 patients with GBM diagnosed at Mayo Clinic after January 1, 2020, and 36 patients with CNS-DLBCL diagnosed at an external institution. Of the patients diagnosed at Mayo Clinic, 47% had MRIs generated from non-Mayo institutions. Two different model approaches were compared: (i) ensemble approach using area under the receiver operating characteristic curve (AUC) and cross-validation for model selection and (ii) loss approach minimizing cross-entropy loss and cross-validation to evaluate prediction performance. The AUCs on the prospective test cohort were 0.84 [95% confidence interval (CI), 0.78–0.90] and 0.83 (95% CI, 0.77–0.88) for the ensemble and loss approaches, respectively. Stability of ensemble prediction improved with the increasing number of models. Stratified AUC analysis demonstrated consistent performance across sex and age. We utilized a robust temporal study design and applied 2 different analytic approaches to develop a classification model. The findings confirm the feasibility of using MRI-based deep learning models to differentiate GBM from CNS-DLBCL. Significance: GBM, IDHwt and CNS-DLBCL are aggressive brain tumors with overlapping MRI features, yet distinct treatment approaches. Noninvasive tools are needed to aid in differential diagnosis. We developed MRI-based deep learning models to differentiate GBM, IDHwt from CNS-DLBCL using a rigorous three-stage temporal design that included prospective validation. The model AUC on a prospective cohort was 0.84.
Design Matters: Challenges and Remedies in CREST-2
Howard, George, Meschia, J, Lal, B, Brott, Thomas G. , Meschia, James F. , Howard, George , Howard, George , Meschia, James F , Lal, Brajesh , Lal, Brajesh K.

Mayo Clinic

Stroke | April 27, 2026 | Volume: 57 | Issue: 5 | Pages: 1481-1484

10.1161/strokeaha.126.055778 | PMID 42044234 Get It

Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals
Ni, Zhanmo , Zhong, Jun , McKean, David, Antwi, Samuel O. , Bracci, Paige M., Du, Mengmeng, Gallinger, Steven, Genkinger, Jeanine, Haiman, Christopher A, Hassan, Manal, Huff, Chad , Kooperberg, Charles, Kastrinos, Fay , LeMarchand, Loic, Lee, WP, Oberg, Ann L. , Park, Margaret A. , Permuth, Jennifer B., Risch, Harvey A., Scheet, Paul , Schwartz, Ann, Shu, Xie, Wolpin, Brian M. , Albanes, Demetrius, Andreotti, Gabriella , Beane-Freeman, Laura, Berndt, Sonja I, Brennan, Paul, Buring, Julie E, Cabrera, Natalia, Campa, Daniele, Chanock, Stephen J, Chung, Charles C., Eliassen, A Heather, Gaziano, J. Michael, Giles, G G, Giovannucci, Edward L, Goggins, Michael, Goodman, Phyllis J. , Hicks, Belynda, Hutchinson, Amy , Jones , Katzke, Verena, Kogevinas, Manolis, Kurtz, Robert C. , Laheru, Daniel, Lee, I, Milne, Roger, Mucci, Lorelei, Patel, Alpa V, Peruchet, Laia, Peters, Ulrike, Porta, Miquel, Rabe, Kari G. , Real, Francisco X, Ricceri, Fulvio, Rothman, Nathaniel, Sesso, Howard D. , Setiawan, Veronica W, Debra, Silverman, Southey, M C, Stampfer, M I, Um, Caroline, Visvanathan, Kala, Wentzensen, Nicolas, Willett, Walter C, Kraft, Peter, Visvanathan, Kala , Zhong, Jun , Zheng, Wei , Canzian, Federico , Malats, Nuria , Duggal, Priya , Klein, Alison P , Chaffee, Kari G. , Antwi, Samuel O , Visvanathan, Kala , Vergara, Candelaria , McKean, David , Connelly, Katelyn E. , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng, Genkinger, Jeanine M. , Haiman, Christopher A. , Hung, Rayjean J. , Kooperberg, Charles , Lynch, Shannon M. , Moore, Steven C. , Permuth, Jennifer B. , Risch, Harvey A., Schwartz, Ann, Stolzenberg‐Solomon, Rachael Z. , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Berndt, Sonja I. , Brennan, Paul, Buring, Julie E. , Cabrera-Castro, Natalia , Canzian, Federico , Chanock, Stephen Jacob , Chen, Yu , Gaziano, J. Michael , Giovannucci, Edward L. , Goggins, Michael , Hicks, Belynda , Katzke, Verena , Kogevinas, Manolis , Laheru, Daniel A. , Malats, Núria , Milne, Roger, Mucci, Lorelei A. , Neale, Rachel Ε. , Orlow, Irene , Peruchet‐Noray, Laia , Peters, Ulrike , Real, Francisco X. , Ricceri, Fulvio , Rothman, Nathaniel , Setiawan, Veronica Wendy , Silverman, Debra T. , Southey, Melissa C , Stampfer, Meir J. , Tobias, Geoffrey S. , Um, Caroline Y. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yu, Kai , Duggal, Priya , Ámundadóttir, Laufey T. , Klein, Alison P.

Mayo Clinic

No container title available | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.21.26351329 | PMID 42078392 Get It

Abstract Pancreatic cancer disproportionately affects Black individuals in the United States, but they have limited representation in genetic studies of pancreatic ductal adenocarcinoma (PDAC). To address this gap, we performed admixture mapping and genome-wide association analysis (GWAS) in genetically inferred African ancestry individuals (1,030 cases and 889 controls). Admixture mapping identified three regions with a significantly higher proportion of African ancestry in cases compared to controls (5q33.3, 10p1, 22q12.3). GWAS identified a genome-wide significant association at 5p15.33 ( CLPTM1L , rs383009:T>C, T Allele Frequency=0.51, OR:1.45, P value=1.24×10 -8 ), a locus previously associated with PDAC. Known loci at 5p15.33, 7q32.3, 8q24.21 and 7q25.1 also replicated (P value <0.01). Multi-ancestral fine-mapping identified two potential causal SNPs (rs3830069 and rs2735940) at 5p15.33. Collectively these findings identified novel PDAC risk loci and expanded our understanding of this deadly cancer in underrepresented populations, emphasizing the multifactorial nature of PDAC risk including inherited genetic and non-genetic factors. Statement of Significance To understand how genetic variation contributes to PDAC risk in Black people in North American, we studied individuals of genetically-inferred African ancestry. We identified novel risk loci and differences in the contribution of known loci. This demonstrates that ancestry-informed genetic analyses improve our understanding of PDAC risk and enhances discovery.
Imaging the later‐life white matter pathologies of repetitive head impacts: A novel pattern revealed through T2 FLAIR MRI
Groh, Jenna R. , Miner, Annalise E., Alshikho, Mohamad J. , Farris, Chad, Cui, Anna, Pettway, Erika, Labonte, Jacob , Mosaheb, Sydney, Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, Charles, Cantu, Robert C., Dodick, David W., Ashton, Nicholas J., Zetterberg, Henrik, Blennow, Kaj, Peskind, Elaine R. , Nowinski, Christopher, Lenio, Steven, Rabinovici, Gil D., Asken, Breton, Rosen, Howard, Blusztajn, Jan Krzysztof , Budson, Andrew E., Turk, Katherine, Goldstein, Lee, Martin, Brett, Palmisano, Joseph N., Dixon, Diane, Schneider, Greta, Steinberg, Eric G., Su, Yi, Protas, Hillary , Pasternak, Ofer, Bouix, Sylvain, Cummings, Jeffrey L., Reiman, Eric M., Shenton, Martha E., Stern, Robert A., McKee, Ann C., Stein, Thor D., Brickman, Adam M., Mez, Jesse, Alosco, Michael L., Rabinovici, Gil D. , Rabinovici, Gil D , Miner, Annalise E., Farris, Chad W. , Cui, Anna, Pettway, Erika C, Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Cantu, Robert C. , Coleman, Michael , Dodick, David W. , Ashton, Nicholas J. , Zetterberg, Henrik , Blennow, Kaj , Ly, Monica T. , Altaras, Caroline , Lenio, Steven , Asken, Breton M. , Cobigo, Yann , Budson, Andrew E. , Turk, Katherine W. , Qiu, Wei Qiao , Palmisano, Joseph , Steinberg, Eric G. , Pasternak, Ofer , Koerte, Inga K , Bouix, Sylvain , Reiman, Eric M. , Shenton, Martha E. , McKee, Ann C. , Stein, Thor D. , Brickman, Adam M. , Mez, Jesse , Alosco, Michael L.

Mayo Clinic

Alzheimer's & Dementia | April 20, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71351 | PMID 42002804 Get It

Abstract INTRODUCTION Repetitive head impacts (RHI) from contact sports may cause a unique pattern of white matter hyperintensities (WMH) on T2‐weighted fluid‐attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI), termed RHI‐associated WMH (RHI‐WMH). These lesions are punctate, circular, and located at the gray–white matter boundary, an area vulnerable to trauma‐related damage. METHODS We investigated the association of RHI with these lesions in two aging cohorts: (1) former American football players versus asymptomatic unexposed men and (2) individuals with RHI from various contact sports versus non‐RHI participants. RHI‐WMH were assessed using visual ratings and a novel automated quantification pipeline. RESULTS Individuals with RHI had greater RHI‐WMH by both detection methods in both cohorts. RHI‐WMH were associated with plasma neurofilament light and p‐tau231, and flortaucipir positron emission tomography (PET) uptake. DISCUSSION RHI‐WMH may represent a new supportive biomarker for the detection of RHI‐related neuropathologies later in life.
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Wen, Patrick Y. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Groot, John de , Lim, Michael, Mellinghoff, Ingo K. , Perry, James, Weller, M, Blondin, Nicholas A., Butt, Omar H. , Damek, Denise M., Fuente, Macarena I. de la , Drappatz, Jan, Dunbar, Erin, Giglio, Pierre , Hyddmark, Emma Viktoria, Iwamoto, Fabio, Jaeckle, Kurt A. , Kim, Lyndon, Kling, Heather M., Lee, Eudocia Q., Mantica, Megan , Mikkelsen, Tom, Newton, Herbert B. , Walbert, Tobias , Weathers, Shiao‐Pei , Lassman, Andrew B. , Group, for the GBM AGILE Regorafenib Study, Alexander, Brian, Anker, Lars , Berry, Nicholas , Cloughesy, Tim, Connelly, Jennifer , Detry, Michelle A. , Fitzgerald, Mark, Gordon, Gary, Graves, Todd, Hu, Jethro , Hyddmark, Emma Maria Viktoria, Johnson, Adam, Kalabic, Marija, Lesser, Glenn J., Marion, Joe , Owen, Scott, Perry, James R, Peters, Katherine B., Powell, Ashley, Saunders, Christina T., Tanner, Kirk, Untch, Sarah, Wilcox, Emma, Yung, W. K. Alfred, Lim, Michael , Buxton, Meredith , de Groot, John , Mellinghoff, Ingo K , Weller, Michael , De La Fuente, Macarena , Lee, Eudocia Q , Mantica, Megan , Nabors, Louis Burt , Newton, Herbert B , Olson, Jeffrey J. , Schiff, David , Walbert, Tobias , Weathers, Shiao-Pei , Cloughesy, Timothy F , Lassman, Andrew B , Berry, Donald , Colman, Howard , Blondin, Nicolas, Drappatz, Jan , Iwamoto, Fabio M., Lee, Eudocia Q. , Mikkelsen, Tom , Nabors, Burt , Newton, Herbert B. , Cloughesy, Timothy F. , Anderson, Mark D., Cavenee, Webster K. , Connelly, Jennifer , Ellingson, Benjamin M. , Galanis, Evanthia , Gordon, Gary, Graber, Jerome J. , Khasraw, Mustafa , Lesser, Glenn J. , McGlothlin, Anna , Peters, Katherine B. , Saunders, Christina T. , Sulman, Erik P. , Tanner, Kirk, Yung, W.K. Alfred

Mayo Clinic

Journal of Clinical Oncology | April 14, 2026 | Volume: 44 | Issue: 18 | Pages: 1676-1686

10.1200/jco-25-01137 | PMID 41980234 Get It

PURPOSE GBM AGILE (ClinicalTrials.gov identifier: NCT03970447 ) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.